ArticleNutrients2023
Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis.
Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Protective effect of rapeseed pollen extract on alcoholic liver injury in mice.Scientific reports · 2026Article
- Dihydroquercetin in Obesity and Prediabetes: Case Report and Insights from Molecular Modeling.International journal of molecular sciences · 2026Article
- Network Pharmacology-Based Analysis Reveals the Mechanisms of the Tibetan Medicinal PlantCurrent issues in molecular biology · 2026Article
- Molecular Mechanism of Dihydroquercetin in Ameliorating Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights Into the HIF-1α/VEGF Pathway.Food science & nutrition · 2026Article
- The herbal pair ofFrontiers in nutrition · 2026Article
- Flavonoids in MASLD: preclinical mechanisms, pharmacological targets, and translational challenges.Frontiers in pharmacology · 2026Review
- Lycopene's Role in Mitigating Obesity-Induced Cardiac Remodeling: Insights Into Inflammatory and MMP-2 Pathways.Molecular nutrition & food research · 2026Article
- Exploring the therapeutic potential of naturally occurring taxifolin, a dietary flavonoid: an updated comprehensive review.Frontiers in pharmacology · 2026Review
- Cuspidatyl Ferulate, a Novel Phenolic Acid fromAntioxidants (Basel, Switzerland) · 2025Article
- Dihydroquercetin in Weight Control: Systematic Review and Meta-Analysis of Preclinical Studies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Taxifolin as a Therapeutic Potential for Weight Loss: A Retrospective Longitudinal Study.Nutrients · 2025Article
- Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs.Biomolecules · 2025Review
- Investigation of Active Components ofInternational journal of molecular sciences · 2024Article
- Silibinin-Loaded Amphiphilic PLGA-Poloxamer Nanoparticles: Physicochemical Characterization, Release Kinetics, and Bioactivity Evaluation in Lung Cancer Cells.Materials (Basel, Switzerland) · 2024Article
- Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury.Molecules (Basel, Switzerland) · 2024Review
- The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Taxifolin Suppresses Inflammatory Responses of High-Glucose-Stimulated Mouse Microglia by Attenuating the TXNIP-NLRP3 Axis.Nutrients · 2023Article
- Identification of ribosomal protein family as immune-cell-related biomarkers of NAFLD by bioinformatics and experimental analyses.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 1 country.
Funding
Abstract
The molecular pathogenesis of nonalcoholic steatohepatitis (NASH) includes a complex interaction of metabolic stress and inflammatory stimuli. Considering the therapeutic goals of NASH, it is important to determine whether the treatment can prevent the progression from NASH to hepatocellular carcinoma. Taxifolin, also known as dihydroquercetin, is a natural bioactive flavonoid with antioxidant and anti-inflammatory properties commonly found in various foods and health supplement products. In this study, we demonstrated that Taxifolin treatment markedly prevented the development of hepatic steatosis, chronic inflammation, and liver fibrosis in a murine model of NASH. Its mechanisms include a direct action on hepatocytes to inhibit lipid accumulation. Taxifolin also increased brown adipose tissue activity and suppressed body weight gain through at least two distinct pathways: direct action on brown adipocytes and indirect action via fibroblast growth factor 21 production in the liver. Notably, the Taxifolin treatment after NASH development could effectively prevent the development of liver tumors. Collectively, this study provides evidence that Taxifolin shows pleiotropic effects for the treatment of the NASH continuum. Our data also provide insight into the novel mechanisms of action of Taxifolin, which has been widely used as a health supplement with high safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.